Silence Therapeutics Plc (SLN) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -15851.9%, revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $559000.00 |
| Revenue (TTM) | $0.0B |
| Net Margin | -15851.9% |
| Return on Equity | -155.8% |
| Operating Margin (TTM) | -9345.1% |
| Current Ratio | 7.42 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | -52.6% |
| FCF Growth (YoY) | -35.5% |
| Altman Z-Score | 8.73 (safe) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
SLN overview · SLN earnings · SLN KPIs · SLN documents · SLN ownership · SLN peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.